

CTI BIOPHARMA CORP  
Form 8-K  
January 20, 2017

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): January 18, 2017

---

CTI BIOPHARMA CORP.  
(Exact name of registrant as specified in its charter)

---

Washington 001-12465 91-1533912  
(State or other jurisdiction of (Commission (I.R.S. Employer  
incorporation or organization) File Number) Identification Number)  
3101 Western Avenue, Suite 600  
Seattle, Washington 98121  
(Address of principal executive offices)  
Registrant's telephone number, including area code: (206) 282-7100  
Not applicable  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 8.01. Other Events.

As previously disclosed, on March 22, 2016, the Nasdaq Stock Market (“Nasdaq”) notified CTI BioPharma Corp. (the “Company”) that its common stock failed to maintain a minimum bid price of \$1.00 over the previous 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). On January 18, 2017, Nasdaq notified the Company that the closing bid price for the Company’s common stock had remained at \$1.00 or greater for ten consecutive business days and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and this matter is now closed.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: January 20, 2017 By: /s/ Louis A. Bianco  
Louis A. Bianco  
Executive Vice President, Finance and  
Administration